Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

NCT01709149 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

711

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: CK-2017357
OTHER: Placebo tablets
DRUG: Riluzole

Sponsor

Cytokinetics